Claims
- 1. Chemical compounds combinations suitable for treatment of vaginal herpes simplex disease comprising:
a physically inert carrier suppository composition which is solid at room temperature and fluid at human body temperature; and a 0.01 to 5.0 wt % concentration of an amino acid selected from the class consisting of 31wherein none, one, two or three of R1, R2, R3 and R4 is methyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether and all others of said R1, R2, R3 and R4 are hydrogen, R5 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether, or acetimidoyl, and R6 is hydrogen, methyl, acetyl, or carbamyl; or 32wherein none, one, two or three of R7, R8, R9 and R10 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R7, R8, R9 and R10 are hydrogen, R11 ism ethyl, acetyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, acetimidoyl, and R12 is hydrogen, methyl, acetyl or carbamyl, or 33
- 2. Chemical compound combination suitable for treatment of herpes simplex disease comprising:
a water soluble physiologically inert compatible base, and a 0.01 to 5.0 wt % concentration of an amino acid selected from the class of consisting of 34wherein none, one, two or three of R1, R2, R3 and R4 is methyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether and all others of said R1, R2, R3 and R4 are hydrogen, R5 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether, or acetimidoyl, and R6 is hydrogen, methyl, acetyl, or carbamyl; or 35wherein none, one, two or three of R7, R8, R9 and R10 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R7, R8, R9 and R10 are hydrogen, R11 is methyl, acetyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ether, acetimidoyl, and R12 is hydrogen, methyl, acetyl or carbamyl; or 36
- 3. A process for treating herpes simplex disease infection of humans comprising:
applying a composition of a water soluble physiologically inert compatible base; and a 0.01 to 5.0 wt % concentration of an amino acid selected from the class consisting of 37wherein none, one, two or three of R1, R2, R3 and R4 is methyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether and all others of said R1, R2, R3 and R4 are hydrogen, R5 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, one to four carbon containing aliphatic ether, or acetimidoyl, and R6 is hydroge n, methyl, acetyl, or carbamyl; or 38wherein none, one, two or three of R7, R8, R9 and R10 is methyl, hydroxyl, one to fur carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R7, R8, R9 and R10 are hydrogen, R11 is methyl, acetyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, acetimidoyl, and R12 is hydrogen, methyl, acetyl or carbamyl; or 39wherein none, one, two or three of R13, R14, R15 and R16 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and none or one of R13, R14, R15 and R16 is imino, all others of said R13, R14, R15 and R16 being hydrogen, and R18 is hydrogen, methyl, acetyl or carbamyl; or 40wherein none, one or two of R20, R21 and R22 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, all others of R20, R21 and R22 being hydrogen, R23 is hydrogen, methyl, acetyl, carbamyl, isopropyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether or isopropenyl, and R24 is hydrogen, methyl, acetyl or carbamyl; or 41wherein none, one, two or three of R30, R32 and R33 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, or amino, all others of R31, R32, R33 being hydrogen, R34 is hydrogen, methyl, acetyl, amino, carbamyl, isopropyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether, or isopropenyl, and R35 is hydrogen, methyl, acetyl or carbamyl; or 42wherein none, one, two or three of R40, R41 and R42 is methyl, hydroxyl, one to four carbon containing aliphatic ester, or one to four carbon containing aliphatic ether and all others of said R40, R41 and R42 are hydrogen, R43 is hydrogen, methyl, ethyl, carbamyl, isopropyl, isopropenyl, hydroxyl, one to four carbon containing aliphatic ether, or acetimidoyl, and R44 is hydrogen, methyl, acetyl, or carbamyl.
RELATED APPLICATION INFORMATION
[0001] This application claims priority from provisional application serial No. 60/160,875, filed Oct. 22, 1999.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60160875 |
Oct 1999 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
09694771 |
Oct 2000 |
US |
Child |
10266928 |
Oct 2002 |
US |